Pair page
KPV with Thymalin
Mechanism-tag overlap and published literature for KPV and Thymalin, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
alpha-msh-c-terminal-anti-inflammatory-tripeptide
thymic-polypeptide-bioregulator-complex
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying KPV and Thymalin have published these mechanism-level observations. Not a co-administration recommendation.
The C-terminal tripeptide of α-MSH. Anti-inflammatory and anti-microbial, with documented activity at melanocortin pathway and downstream NF-κB suppression. Sometimes paired with Thymalin in inflammatory bowel and dermatologic protocols to combine thymic immune restoration (Thymalin) with mucosal anti-inflammatory and anti-microbial activity (KPV). No formal combination data; theoretical compatibility based on non-overlapping primary targets.
Quick facts
KPV
Thymalin
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2016 | KPV | Viennois E, Ingersoll SA, Ayyadurai S, et al. Critical Role of PepT1 in Promoting Colitis-Associated Cancer and Therapeutic Benefits of the Anti-inflammatory PepT1-Mediated Tripeptide KPV in a Murine Model. Cell Mol Gastroenterol Hepatol. 2016;2(3):340-357. | preclinical, in vivo |
| 2014 | KPV | Xiao B, Laroui H, Viennois E, et al. Nanoparticles with surface antibody against CD98 and carrying CD98 small interfering RNA reduce colitis in mice. Gastroenterology. 2014;146(5):1289-1300.e1-19. | preclinical, in vivo |
| 2010 | KPV | Kannengiesser K, Lügering A, Maaser C, Domschke W, Luger TA, Kucharzik T. Treatment of murine colitis with the tripeptide KPV-review of recent findings. Falk Symp. 2010. | preclinical, in vivo |
| 2008 | KPV | Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, Bohm M, Luger TA, Domschke W, Kucharzik T. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331. PMID: 180… PMID 18092346 | preclinical, in vivo |
| 2008 | KPV | Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. α-Melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2… PMID 18612027 | preclinical, in vivo |
| 2013 | KPV | Coco R, Plapied L, Pourcelle V, Jérôme C, Brayden DJ, Schneider YJ, Préat V. Drug delivery to inflamed colon by nanoparticles: comparison of different strategies. Int J Pharm. 2013;440(1):3-12. PMID: 22939963. PMID 22939963 | research article |
| 2009 | KPV | Capsoni F, Ongari AM, Reali E, Catania A. Melanocortin peptides inhibit urate crystal-induced activation of phagocytic cells. Arthritis Res Ther. 2009;11(5):R151. PMID: 19814815. PMID 19814815 | research article |
| 2008 | KPV | Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. PMID: 18061177. PMID 18061177 | research article |
| 2021 | Thymalin | Khavinson VK, Kuznik BI, Tarnovskaya SI, Linkova NS. Results and Prospects of Using Activator of Hematopoietic Stem Cell Differentiation in Complex Therapy for Patients with COVID-19. Stem Cell Rev Rep. 2021 Feb;17(1):285-290. doi: 10.1007/s12015-020-10087-6. PMID: 33575961. (Re… PMID 33575961 | human study |
| 2020 | Thymalin | Khavinson V, Linkova N, Dyatlova A, Kuznik B, Umnov R. Peptides: Prospects for Use in the Treatment of COVID-19. Molecules. 2020 Sep 24;25(19):4389. doi: 10.3390/molecules25194389. PMID: 32987757. (Computational and mechanistic review of Khavinson short peptides — including the… PMID 32987757 | human study |
| 2020 | Thymalin | Khavinson VK, Kuznik BI, Volchkov VA, Rukavishnikova SA, Titova ON, Akhmedov TA, Trofimova SV, Ryzhak GA, Potyomkin VV, Saginbaev UR. Effect of thymalin on adaptive immunity in complex therapy for patients with COVID-19. Klinicheskaya Meditsina (Russian Journal). 2020;98(8):593-… | human study |
| 2020 | Thymalin | Lukyanov SA, Kuznik BI, Shapovalov KG, Khavinson VK, Smolyakov YN, et al. Thymalin as a Potential Alternative in the Treatment of Severe Acute Respiratory Infection Associated with SARS-CoV-2. Int J Immunol Immunother. 2020;7:055. (Severe-COVID-19 case treated with Thymalin 10 m… | human study |
| 2003 | Thymalin | Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003 Jun-Aug;24(3-4):233-240. PMID: 14523363. (266-patient elderly geroprotective trial; 6–8-year follow-up; mortality reductions of 2.0-fold for Thymalin alone, 2.5-fold fo… PMID 14523363 | human study |
| 1986 | Thymalin | Kuznik BI, Makhakova GCh, Morozov VG, Pisarevskaia LI, Khavinson VKh. [Effect of thymalin on thrombocyte aggregation and the antiaggregation activity of the vascular wall in intact and thymectomized rats]. Biull Eksp Biol Med. 1986 Aug;102(8):200-202. Russian. PMID: 3754821. (Ea… PMID 3754821 | preclinical, in vivo |
| 1982 | Thymalin | Anisimov VN, Khavinson VKh, Morozov VG. Carcinogenesis and aging. IV. Effect of low-molecular-weight factors of thymus, pineal gland and anterior hypothalamus on immunity, tumor incidence and life span of C3H/Sn mice. Mech Ageing Dev. 1982 Jul;19(3):245-258. doi: 10.1016/0047-63… | preclinical, in vivo |
| 2022 | Thymalin | Avolio F, Martinotti S, Khavinson VK, Esposito JE, Giambuzzi G, Marino A, Mironova E, Pulcini R, Robuffo I, Bologna G, Simeone P, Lanuti P, Guarnieri S, Trofimova S, Procopio AD, Toniato E. Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macr… PMID 35408963 | preclinical, in vitro |
| 2020 | Thymalin | Khavinson VK, Linkova NS, Kvetnoy IM, Polyakova VO, Drobintseva AO, Kvetnaya TV, Ivko OM. Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells. Bull Exp Biol Med. 2020 Nov;170(1):118-122. doi: 10.1007/s10517-020-05016-z. PMID: 33237528. (In vitro demonstrati… PMID 33237528 | preclinical, in vitro |
| 2016 | Thymalin | Linkova NS, Drobintseva AO, Orlova OA, Kuznetsova EP, Polyakova VO, Kvetnoy IM, Khavinson VK. Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro. Bull Exp Biol Med. 2016 May;161(1):175-178. doi: 10.1007/s10517-016-3370-x. PMID: 27259484. (Khavinson short… PMID 27259484 | preclinical, in vitro |
| 2017 | Thymalin | Khavinson V, Popovich I. Short Peptides Regulate Gene Expression, Protein Synthesis and Enhance Life Span. In: Vaiserman AM (ed.). Anti-aging Drugs: From Basic Research to Clinical Practice. RSC Drug Discovery Series No. 57. Royal Society of Chemistry; 2017. Chapter 20, pp. 496–… | mechanism / discovery |
| 2016 | Thymalin | Khavinson VK, Lin'kova NS, Tarnovskaya SI. Short Peptides Regulate Gene Expression. Bull Exp Biol Med. 2016 Nov;162(2):288-292. doi: 10.1007/s10517-016-3596-7. PMID: 27909961. (Khavinson group's short-peptide DNA-binding / gene-expression-regulation hypothesis, the mechanistic f… PMID 27909961 | mechanism / discovery |
Related pair pages
More research context
Frequently asked
Have KPV and Thymalin been studied together?
Researchers have published mechanistic-level co-administration discussion of KPV and Thymalin. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do KPV and Thymalin share?
KPV and Thymalin do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of KPV and Thymalin?
KPV: Not approved. Thymalin: Not approved (US). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on KPV and Thymalin?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the KPV profile and the Thymalin profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026